Zürcher Nachrichten - Pfizer offers to sell medicines at cost to poorest countries

EUR -
AED 3.834856
AFN 72.981026
ALL 98.491871
AMD 410.574545
ANG 1.873597
AOA 958.441534
ARS 1062.068709
AUD 1.668164
AWG 1.879297
AZN 1.774656
BAM 1.956632
BBD 2.099092
BDT 124.232814
BGN 1.958008
BHD 0.392267
BIF 3073.606664
BMD 1.044054
BND 1.4119
BOB 7.184054
BRL 6.348575
BSD 1.039642
BTN 88.383574
BWP 14.369109
BYN 3.402246
BYR 20463.455505
BZD 2.089788
CAD 1.4984
CDF 2996.434335
CHF 0.932371
CLF 0.037427
CLP 1032.725839
CNY 7.619298
CNH 7.624449
COP 4583.396412
CRC 524.522987
CUC 1.044054
CUP 27.667427
CVE 110.312953
CZK 25.108921
DJF 185.128703
DKK 7.458302
DOP 63.306913
DZD 140.708819
EGP 53.090769
ERN 15.660808
ETB 129.594994
FJD 2.419125
FKP 0.826872
GBP 0.82945
GEL 2.934095
GGP 0.826872
GHS 15.282497
GIP 0.826872
GMD 75.171679
GNF 8981.818386
GTQ 8.010405
GYD 217.502466
HKD 8.11186
HNL 26.390219
HRK 7.4889
HTG 136.00782
HUF 413.977438
IDR 16852.07323
ILS 3.801792
IMP 0.826872
INR 88.729074
IQD 1361.878967
IRR 43941.619435
ISK 145.113457
JEP 0.826872
JMD 162.65915
JOD 0.740338
JPY 163.428363
KES 134.213278
KGS 90.832546
KHR 4177.776073
KMF 486.659583
KPW 939.647883
KRW 1514.838471
KWD 0.321516
KYD 0.866368
KZT 545.98211
LAK 22754.673557
LBP 93096.577585
LKR 305.22976
LRD 188.690217
LSL 19.139837
LTL 3.08282
LVL 0.631537
LYD 5.108172
MAD 10.463148
MDL 19.149141
MGA 4905.085269
MKD 61.561171
MMK 3391.046186
MNT 3547.694854
MOP 8.322738
MRU 41.345577
MUR 49.280896
MVR 16.080872
MWK 1802.251891
MXN 20.95141
MYR 4.682524
MZN 66.718935
NAD 19.139837
NGN 1614.576632
NIO 38.256264
NOK 11.798806
NPR 141.414119
NZD 1.845107
OMR 0.401651
PAB 1.039642
PEN 3.871246
PGK 4.215792
PHP 61.207138
PKR 289.37392
PLN 4.260093
PYG 8106.446244
QAR 3.789911
RON 4.977322
RSD 117.017747
RUB 107.411783
RWF 1449.216096
SAR 3.922094
SBD 8.752883
SCR 14.548185
SDG 628.007273
SEK 11.498155
SGD 1.414228
SHP 0.826872
SLE 23.801848
SLL 21893.290418
SOS 594.152588
SRD 36.678625
STD 21609.806806
SVC 9.096867
SYP 2623.21688
SZL 19.135135
THB 35.777638
TJS 11.373235
TMT 3.664629
TND 3.312708
TOP 2.445276
TRY 36.741769
TTD 7.056
TWD 34.125736
TZS 2521.389855
UAH 43.600836
UGX 3813.621262
USD 1.044054
UYU 46.369713
UZS 13403.698233
VES 53.742914
VND 26555.509733
VUV 123.952164
WST 2.884499
XAF 656.235982
XAG 0.035143
XAU 0.000398
XCD 2.821607
XDR 0.793037
XOF 656.235982
XPF 119.331742
YER 261.404956
ZAR 19.098632
ZMK 9397.736499
ZMW 28.771231
ZWL 336.184914
  • CMSD

    0.0000

    23.56

    0%

  • SCS

    -0.5800

    11.74

    -4.94%

  • BCC

    -0.2600

    122.75

    -0.21%

  • BCE

    0.0500

    23.16

    +0.22%

  • GSK

    0.1700

    33.6

    +0.51%

  • RIO

    -0.0900

    58.64

    -0.15%

  • NGG

    0.8200

    58.5

    +1.4%

  • CMSC

    0.0200

    23.86

    +0.08%

  • JRI

    0.1100

    12.06

    +0.91%

  • RBGPF

    59.9600

    59.96

    +100%

  • RELX

    -0.3100

    45.47

    -0.68%

  • AZN

    0.9100

    65.35

    +1.39%

  • BTI

    0.1131

    36.24

    +0.31%

  • VOD

    0.0100

    8.39

    +0.12%

  • RYCEF

    -0.0100

    7.27

    -0.14%

  • BP

    0.1900

    28.6

    +0.66%

Pfizer offers to sell medicines at cost to poorest countries
Pfizer offers to sell medicines at cost to poorest countries / Photo: LUCA SOLA - AFP/File

Pfizer offers to sell medicines at cost to poorest countries

US pharmaceutical giant Pfizer on Wednesday said it would sell its patented drugs on a not-for-profit basis to the world's poorest countries, as part of a new initiative announced at the World Economic Forum in Davos.

Text size:

"The time is now to begin closing this gap" between people with access to the latest treatments and those going without, chief executive Albert Bourla told attendees at the exclusive Swiss mountain resort gathering.

"An Accord for a Healthier World" focuses on five areas: infectious diseases, cancer, inflammation, rare diseases and women's health -- where Pfizer currently holds 23 patents, including the likes of Comirnaty and Paxlovid, its Covid vaccine and oral treatment.

"This transformational commitment will increase access to Pfizer-patented medicines and vaccines available in the United States and the European Union to nearly 1.2 billion people," Angela Hwang, group president of the Pfizer Biopharmaceuticals Group, told AFP.

Five countries: Rwanda, Ghana, Malawi, Senegal and Uganda have committed to joining, with a further 40 countries -- 27 low-income and 18 lower-middle-income -- eligible to sign bilateral agreements to participate.

"Pfizer's commitment sets a new standard, which we hope to see emulated by others," Rwanda's President Paul Kagame said.

But he added that "additional investments and strengthening of Africa's health systems and pharmaceutical regulators" would also be needed.

- Seven years behind -

Developing countries experience 70 percent of the world's disease burden but receive only 15 percent of global health spending, leading to devastating outcomes.

Across sub-Saharan Africa, one child in 13 dies before their fifth birthday, compared to one in 199 in high-income countries.

Cancer-related mortality rates are also far higher in low and middle-income countries -- causing more fatalities in Africa every year than malaria.

All this is set to a backdrop of limited access to the latest drugs.

Essential medicines and vaccines typically take four to seven years longer to reach the poorest countries, and supply chain issues and poorly resourced health systems make it difficult for patients to receive them once approved.

"The Covid-19 pandemic further highlighted the complexities of access to quality healthcare and the resulting inequities," said Hwang.

"We know there are a number of hurdles that countries have to overcome to gain access to our medicines. That is why we have initially selected five pilot countries to identify and come up with operational solutions and then share those learnings with the remaining countries."

- 'Very good model' -

Specifically, the focus will be on overcoming regulatory and procurement challenges in the countries, while ensuring adequate levels of supply from Pfizer's side.

The "not-for-profit" price tag takes into account the cost to manufacture and transport of each product to an agreed upon port of entry, with Pfizer charging only manufacturing and minimum distribution costs.

If a country already has access to a product at a lower price tier, for example vaccines supplied by GAVI, a public-private global partnership, that lower price will be maintained.

Hwang acknowledged that even an at-cost approach could be challenging for the most cash-strapped countries, and "this is why we have reached out to financial institutions to brief them on the Accord and ask them to help support country level financing."

Pfizer will also reach out to other stakeholders -- including governments, multilateral organizations, NGOs and even other pharmaceuticals -- to ask them to join the Accord.

It is also using funding from the Bill & Melinda Gates Foundation to advance work on a vaccine against Group B Streptococcus (GBS), the leading cause of stillbirth and newborn mortality in low-income countries.

"This type of accord is a very good model, it's going to help get medicines out," Gates told the Davos conference, adding that "partnerships with companies like Pfizer have been key to the progress we have made" on efforts like vaccines.

G.Kuhn--NZN